Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 1, 2020, details significant corporate actions completed by Cryoport, Inc. (NASDAQ: CYRX) on that date. The Company, a provider of temperature-controlled logistics solutions, executed two major acquisitions and a concurrent private placement financing to fund the transactions.
Key Financial Metrics and Transactions
- Acquisitions:
- CRYOPDP Acquisition: Completed the acquisition of CRYOPDP, a global provider of temperature-controlled logistics for clinical research and pharmaceutical markets.
- MVE Cryobiological Acquisition: Completed the acquisition of Chart Industries, Inc.'s MVE cryobiological storage business.
- Private Placement Financing:
- Total Proceeds: $275,000,000 raised from an investment vehicle affiliated with The Blackstone Group Inc.
- Series C Preferred Stock: Issued 250,000 shares at $1,000 per share ($250,000,000 total). Features a 4.0% annual dividend paid in-kind and senior liquidation rights.
- Common Stock: Issued 675,536 shares for $25,000,000.
- Debt and Liquidity: The filing does not provide specific pre-transaction debt levels or liquidity ratios. Proceeds were used to finance a portion of the MVE Acquisition closing payment.
Material Changes and Governance
The Company's capital structure and governance underwent material changes effective October 1, 2020:
- Board Expansion: The Board of Directors increased from six to seven members.
- New Director: Ram Jagannath, a Senior Managing Director at Blackstone, was appointed to the Board. Blackstone holds the right to nominate one director as long as it holds 66.67% of the Series C Preferred Stock.
- Security Rights: The Series C Preferred Stock includes specific voting rights, consent rights regarding indebtedness (limiting debt-to-EBITDA ratio to 5-to-1), and redemption rights exercisable by the Company or Holders under specific conditions.
Outlook, Risks, and Contingencies
The filing focuses on the completion of transactions rather than forward-looking financial guidance. Key contingencies and risks include:
- Financial Statement Filing: Financial statements for the acquired businesses (MVE and CRYOPDP) are not included in this report and will be filed by amendment within 71 days.
- Debt Covenants: The Series C Preferred Stock agreement restricts the incurrence of new indebtedness unless the pro forma debt-to-LTM EBITDA ratio remains below 5-to-1.
- Standstill Agreement: Blackstone is subject to standstill restrictions preventing it from seeking additional board representation or proposing changes of control while holding the director nomination right.
Investor Verification Checklist
- Verify the pro forma financial impact of the MVE and CRYOPDP acquisitions once the required financial statements are filed within 71 days.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for detailed terms regarding dividend accrual, conversion mechanics, and liquidation preferences.
- Monitor the Company's debt levels to ensure compliance with the 5-to-1 debt-to-EBITDA covenant imposed by the Series C Preferred Stock.
- Confirm the integration progress of the MVE cryobiological storage business and CRYOPDP logistics operations.